AzTrials
AzTrials

Diabetes Mellitus, Type 2NCT04874116

Decreasing Cardiovascular Risk for Patients With Diabetes

A study testing Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging and Mobile text messaging in people with Diabetes Mellitus, Type 2, run by Michigan State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cardiovascular disease (CVD) complications are the leading cause of diabetes mellitus (DM)-related morbidity and mortality, creating a significant burden on the public health system. This burden is, in part, attributable to poor medication adherence, with 21-42% of patients failing to properly adhere to their care. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetes Mellitus, Type 2
What is being tested?
Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging and Mobile text messaging
Could I receive a placebo?
No, everyone receives an active treatment
How many people
404 participants
Where
1 siteUnited States
Study dates
26 May 2021to 28 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients: aged >18 at participating Federally Qualified Health Care centers (FQHCs) and; 1) have a diagnosis of Type 2 diabetes (T2DM) with HbA1c >8, with or without CVD; 2) patient should be taking at least one prescribed medication for BP or cholesterol management 3) able to provide informed consent 4) able to read and speak English (grade 6 reading level); 5) have a cell phone with texting (provided by our study for any enrolled patient who does not have one).

Who cannot join

  • 1) medical record documentation of cognitive impairment, dementia or psychosis 2) plans to leave the area prior to study completion 3) participating in another cellphone program.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Ingham Healthcare center

    Lansing, Michigan, 48742

Other trials in United States

About this study

Official title: Improving Diabetic Patients' Adherence to Treatment and Prevention of Cardiovascular Disease

Cardiovascular disease (CVD) complications are the leading cause of diabetes mellitus (DM)-related morbidity and mortality, creating a significant burden on the public health system. This burden is, in part, attributable to poor medication adherence, with 21-42% of patients failing to properly adhere to their care. Importantly, this issue is especially pronounced in minority and low-income populations, which show higher rates of chronic illness and lower medication adherence. Interventions that foster and reinforce patient-centered communication between clinicians and patients show promise in improving health outcomes. However, they have not been widely implemented, in part due to a lack of compelling evidence for their effectiveness in primary care settings. Project Objective: The investigators propose to evaluate the impact of a patient activation program: Office Guidelines Applied to Practice (Office-GAP) combined with mobile text messaging reinforcement (Way to Health [W2H]) on medication adherence in patients with DM compared to mobile texting alone. Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. W2H is a texting service that informs and encourages patients to adhere to goals and improve communication. The long-term goal is to develop a model that can reliably improve and sustain adherence and can be successfully implemented in primary care clinics to close the morbidity and mortality gap for minority/low-income DM patients. The hypothesis is that the combined face-to-face patient activation and texting- delivered reinforcement methods will facilitate communication between patients and providers, improving the frequency, accuracy, and timeliness of communication while reinforcing shared goals and engendering mutual respect more than texting alone. Improved communication between patients and providers may improve medication adherence, blood sugar, cholesterol, blood pressure control, and patient satisfaction with providers, and ultimately decrease burden of illness.

Research Strategy: The investigators will conduct a randomized community-based clinical trial in Federally-Qualified Health Centers (FQHCs) in Michigan enrolling 378 patients in 17 teams. All patients will receive usual care and medication for DM and CVD prevention. Eight teams will use W2H alone, and 9 teams will combine Office-GAP with WTH. The investigators will evaluate the impact of shared decision-making strategies for patients and providers.

Impact: If successfully translated to clinical practice, these interventions have the potential to significantly impact patient care in FQHCs, improving outcomes for DM and CVD. This research also paves the way for shifting clinical practice across a spectrum of chronic disease where medication non-adherence is an issue.

Read the detailed description

Study design and overview: The investigators will conduct this study with 17 teams in 12 clinics that serve low-income patients: Federally Qualified Health Centers (FQHC's). The goal of the study is to evaluate how well the approach to improving patient outcomes with a blend of communication strategies works in real-world settings compared to mobile phone texting alone. Each team will be randomly assigned to one of two groups: the Intervention (Group 1): includes a patient group meeting + a checklist used during each medical visit (together called Office-GAP) along with text messaging in between visits; the Control (Group 2) includes only the text messages.

Randomization: The investigators will recruit 22 diabetes (DM) patients per team. All patients at a particular team will participate in the same group (intervention or control). The investigators chose this approach because it is realistic for providers and patients at a team to follow a similar approach. This also helps the comparison of control and intervention groups to be more accurate because there is less chance of mixing between the two groups. In Michigan, FQHCs have similar numbers and types of providers (internal and family medicine) and nurse practitioners.

Methods. Setting: Because the investigators are interested in how well the interventions may address disparities in health outcomes for low-income and minority patients, they are recruited from FQHCs who serve these populations in Michigan. FQHC patients are mainly below federal poverty levels (92% of participants); 56% are non-white; 91% are uninsured or covered by Medicaid. Sample: A total of 378 patients, men and women, with Type II diabetes that is not well-controlled (the standard will be a score for the HbA1c test equal to or higher than 8) will be recruited. In the investigators' pilot studies, 80% of patients who met these criteria agreed to participate. In the pilot, about 10% dropped out before follow-up at 3 months and a further 3% dropped out before completion. A 20% dropout rate is anticipated. Recruiting 378 patients will result in 320 patients retained by the end of the 5 year study. Based on the pilot study and feedback from clinics, it is estimated that the enrollment goal will be reached within 4 years. Each FQHC will have at least 200 DM patients who meet the criteria.

Patient Intervention procedures: Patients will participate either in the intervention group (Office-GAP + Texting) or in the control group (Texting only) as described below. All patients will receive medical treatment-as-usual from the participating clinics, consisting of diabetes care, usual preventive care, and other medical treatment as needed.

Office-GAP Intervention (Patient Activation Intervention): The investigators have described the Office-GAP intervention in previous peer-reviewed publications (1-3). Briefly, after recruitment, patients in the Office-GAP group will attend: 1) one scheduled group visit, (90-120 min; 4-6 patients at a time); 2) one follow-up visit with their providers within one month, and then at 3, 6, 9, and 12 months after the group visit. At these follow-up visits, providers will complete the Office-GAP Checklist, which evaluates medication prescribing behavior. In addition, shared decision-making (SDM) and goal setting occurs between patient and provider. These follow-up visits are patients' regularly scheduled visits with their providers and not additional to their usual care.

At the group visit: Research Assistants will obtain informed consent/HIPAA authorization from patients after introducing them to the study; Group 1: Office-GAP + Texting session: the group visit is a Shared Decision Making (SDM) activation session wherein patients learn self-management behaviors, communication skills, and use of decision support tools (DSTs). They also learn how to use the eCap electronic pill container to monitor medication adherence; learn to use Way to Health Texting service and confirm set up on their mobile phone. Group 2: For the texting only group: participants will learn how to use Way to Health Texting service and confirm set up on their mobile phone, and learn how to use the eCap electronic pill container to monitor medication adherence. They will not experience the Office-GAP intervention. Both groups will also complete baseline study questionnaires during the group visit.

Office-GAP Follow-up visit with providers: the Office-GAP Checklist. The Office-GAP Checklist is the core tool of the SDM intervention. A one-page checklist, this SDM tool outlines all evidence-based medications for secondary prevention of cardiovascular disease (CVD) in T2DM patients. It is an in-consultation decision support tool that helps engage the patient and provider to encourage and enhance an SDM process via discussion of medication and secondary prevention/lifestyle changes during an office visit. In this study, the Office-GAP Checklist will be completed by the provider with direct patient involvement during the office visits at 0-1, 3, 6, 9 and 12 months. Only Group 1 patients will use this checklist during their office visits.

The Office-GAP Checklist also serves as a provider reminder at the point of care, because the provider records a check-mark for each medication: "Yes" (if patient is on the medication), "No" (if patient is not), or "Does not apply to me because…" A reason for exclusion of a medication is also provided (patient is not eligible for the medication, has a contraindication to its use, or the patient and provider have identified an alternative due to side effect or cost concerns). Details about the next appointment and any secondary prevention plan changes are also listed on the form. At the end of the visit, both patient and provider sign the form to confirm that they have reviewed the checklist. The patient receives a copy of the checklist to take home and a copy is retained in the patient record. All providers in the intervention teams receive a brief provider education in Office-GAP tool use and communication skills (described below C.4.15).

Educational tool literacy standards. Office-GAP has been rigorously adapted for use with low health literacy patients. All study materials are grade 6 reading level.

Mobile DM self-management texting intervention (Way to Health Texting Program). During group visits, all patients in both groups will be taught how to send and receive text messages on their phone. The Way to Health service does not require patients to use a special app. Way to Health engages patients in two ways: 1) Patients receive daily Way to Health messages appropriate to their diagnosis and medications (e.g. BP, blood glucose, medication) and appointment reminders throughout the study. They also receive informational and educational texts. 2) Patients respond to prompts, and may contact their providers' office throughout the study via texting. Patients will receive additional diabetic modules that follow the standard for diabetes education for the rest of the 12 months once the initial 15 week program is complete. The Way to Health texting program will be used to encourage T2DM patients to maintain communication with their providers, improve medication adherence, and other secondary prevention and self-care between visits. Daily messages may take the form of reminders, prompts, education, or reinforcement. Sample message texts include "Did you take your medications today?" and "How many times did you check your feet for wounds this week?" The pilot found the program to be usable and effective for both patients and providers.

Provider and Practice Staff Training. All intervention providers will participate in an interactive orientation which has been shown to promote behavioral change among health professionals. Providers will be asked to agree to participate in the study before the session. Provider/Staff Educational module: The training session is 90 minutes long. The session is scheduled at multiple times to meet providers' needs. In the pilot Office-GAP study, there was 100% participation by providers. The training module, delivered by the PI and Dr. Karen Kelly-Blake, includes: 1) brief presentations on effectiveness and cost-effectiveness of medical therapy and behavior changes in management of T2DM, blood pressure, and heart disease; 2) a hands-on practice session for providers to elicit patients' preferences and values; 3) an introduction to the Office-GAP Checklist and best practices for using it during a patient encounter; 4) review of the Smith evidence-based patient-centered method for establishing trust, communicating clearly, and engaging in goal-setting with patients. Providers will have a chance to practice skills using Braddock and Elwyn's approach to role-playing to model office visits; and 5) a complete pre-and post-training survey (before and after the training session) to determine provider attitudes about the use of DSTs, SDM, and mHealth in their practice and an end of study semi-structured interview. The investigators are highly experienced in provider training.

Analysis of outcomes: The primary outcome (medication adherence - how well patients adhere to their providers' advice to take medications) will be assessed in each individual patient by e-CAP monitoring, a device that signals when patients open their prescription medication bottles. The investigators will conduct preliminary analysis of study hypotheses at 6mo and 12mo using standard statistical tests. A comparison of Office-GAP plus Way to Health teams (Group 1) to Way to Health only teams (Group 2) at baseline will be conducted to be sure the patient populations are similar in terms of health characteristics that may influence the results. If substantive differences are found, the investigators will be able to control for these in subsequent analyses using statistical regression techniques. This method assures a degree of dissimilarity rather than assuming all of the clinical populations are identical. Equivalence between the groups will be assessed based on demographic factors such as age, gender, education, race/ethnicity.

Being tested
Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging, Mobile text messaging
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Office Guidelines Applied to Practice (Office-GAP) + Mobile text messagingBehavioural

    Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.

  • Mobile text messagingBehavioural

    Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.

Study groups in NCT04874116
Study groupRoleWhat they receive
Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messagingExperimentalParticipants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.
Receives: Behavioral: Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging
Mobile phone text messagingActive comparatorParticipants receive mobile phone text messaging alone for 12 months.
Receives: Behavioral: Mobile text messaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Medication adherence

    eCAP records real-time adherence data, tracking each opening with date and time

    Measured: Progression of adherence over 12 months

  2. Change in Medication adherence

    Adherence to Refills and Medication (ARMs).

    Measured: Progression of adherence over 12 months

  3. Change in Medication Adherence

    Survey to assess medication adherence

    Measured: Progression of adherence over 12 months

Secondary outcomes (3)
  1. Change in UK Prospective Diabetes Study (UKPDS)

    Diabetes-specific 10-year CVD and stroke risk

    Measured: Progression of risk over 12 months

  2. Change in Patient activation measure

    13-item scale that reflects a developmental model of activation.

    Measured: Progression of activation model over 12 months

  3. Change in CollaboRATE

    Measures level of shared decision-making in clinical encounter from patient's perspective. 3-question survey. Scale of 1 = no effort was made to 10 = every effort was made. Higher score indicates higher measure of shared decision-making between patient and provider.

    Measured: Progression of shared decision-making over 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2021
  2. Study start26 May 2021
  3. Primary completion28 Apr 2026
  4. Study completion28 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
Office-GAP is a Patient Activation Intervention Program for Group 1 that includes: 1) Group visit 2) Provider training for patient activation, and 3) Office-GAP checklist used in the office. Patients in Groups 1 and 2 will attend one group visit and 5 follow-up visits with their provider in 1 month, 3, 6, 9 and 12 months after the group visit. For Group 1, the group visit is a shared decision making (SDM) activation session wherein patients learn self-management behaviors, medication use, communication skills, and use of decision support tools (DST). The Office-GAP Checklist is an in-consultation DST that helps engage the patient and provider in initiating and enhancing a SDM process via discussion of medication and secondary prevention/lifestyle changes. Way to Health is a text-based DM self-management program. Groups 1 and 2 receive a 15-week customized program of text messages after the group visit. For the remaining 12 months, they will receive standard diabetic education modules.
Masking
None (open label)
Enrolment
404 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04874116
Sponsor's protocol ID
R01HL149777-01A1
Status last verified
Oct 2026
First submitted
1 Mar 2021
Last updated
3 Nov 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The IPD that will be shared will be related to the IPD that underlie results in a publication when requested.

Publications

  • Olomu A, Hart-Davidson W, Luo Z, Kelly-Blake K, Holmes-Rovner M. Implementing shared decision making in federally qualified health centers, a quasi-experimental design study: the Office-Guidelines Applied to Practice (Office-GAP) program. BMC Health Serv Res. 2016 Aug 2;16(a):334. doi: 10.1186/s12913-016-1603-3.

    PubMed 27484348
  • Olomu A, Khan NN, Todem D, Huang Q, Kumar E, Holmes-Rovner M. The Office Guidelines Applied to Practice program improves secondary prevention of heart disease in Federally Qualified Healthcare Centers. Prev Med Rep. 2016 Jun 29;4:357-63. doi: 10.1016/j.pmedr.2016.06.020. eCollection 2016 Dec.

    PubMed 27512651
  • Olomu A, Khan NNS, Todem D, Huang Q, Bottu S, Qadri S, Holmes-Rovner M. Blood Pressure Control in Hypertensive Patients in Federally Qualified Health Centers: Impact of Shared Decision Making in the Office-GAP Program. MDM Policy Pract. 2016 Jul 7;1(1):2381468316656010. doi: 10.1177/2381468316656010. eCollection 2016 Jul-Dec.

    PubMed 30288401
  • Olomu A, Kelly-Blake K, Hart-Davidson W, Gardiner J, Luo Z, Heisler M, Holmes-Rovner M. Improving diabetic patients' adherence to treatment and prevention of cardiovascular disease (Office Guidelines Applied to Practice-IMPACT Study)-a cluster randomized controlled effectiveness trial. Trials. 2022 Aug 15;23(1):659. doi: 10.1186/s13063-022-06581-6.

    PubMed 35971135

Questions about this trial

What is this clinical trial studying?

A study testing Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging and Mobile text messaging in people with Diabetes Mellitus, Type 2, run by Michigan State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Medication adherence (time frame: Progression of adherence over 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04874116, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in